Dofil is relevant in contexts involving heightened systemic burden, as it is commonly used for managing symptomatic distress associated with infections caused by susceptible fungi, such as the Candida and Cryptococcus species. The medication may be part of symptomatic management across a wide range of fungal conditions, from localized discomfort to serious disease.

Therapeutic Focus and Symptomatic Relief

The medication is commonly used across conditions presenting with systemic or localized discomfort, relevant in situations involving serious, deep-seated infections like candidemia and cryptococcal meningitis, as well as recurrent or episodic manifestations affecting the mucous membranes, including oropharyngeal thrush and vaginal candidiasis.

It is used for managing symptom clusters that may become intense or disruptive, such as soreness, itching, and difficulty swallowing. Providing supportive relief when symptoms interfere with routine activities, Dofil assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.

Dofil is also applied in clinical settings when supportive symptom management is appropriate in contexts involving the prophylactic management of high-risk groups, such as those undergoing cytotoxic therapy. This use supports the patient during difficult episodes by easing distress.

Quick Fact: Symptomatic Support is often provided for Infection-Related Discomfort

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Dofil?

Official regulatory documents define strict eligibility criteria for Dofil use.

Contraindicated Populations

Use is contraindicated for patients with a known hypersensitivity to fluconazole or other azole compounds. This prohibition also applies to individuals concurrently taking specific QT-prolonging medications metabolized by the CYP3A4 enzyme, such as pimozide, due to the risk of serious cardiac events. Furthermore, the oral forms are contraindicated for patients with certain rare hereditary sugar intolerances (e.g., galactose or sucrose malabsorption).

Restricted and Conditional Use

Eligibility is defined across all age groups, from adults to neonates (from birth), with usage for all pediatric indications established from six months of age. Older adults are generally eligible, but the dosage must be adjusted according to their renal function. Eligibility is restricted in patients with impaired renal function (CrCl leq 50 mL/min), which requires a mandated maintenance dose reduction. Caution and monitoring are required for patients with pre-existing liver dysfunction or potentially proarrhythmic cardiac conditions.

Pregnancy and Lactation

The chronic use of high doses (400–800 mg/day) during the first trimester of pregnancy is contraindicated. A single low dose requires careful consideration. For lactation, use is permitted after a single low dose, but it is not recommended following repeated or high-dose regimens.

Interactions with other medicines and products

Official regulatory information for Dofil is structured around two primary interaction risks: increased plasma levels of Dofil and increased risk of serious heart rhythm abnormalities (Torsade de Pointes).

Contraindicated Combinations

Specific medicines and drug classes are contraindicated (must not be used) with Dofil due to their documented potential to significantly raise Dofil's concentration in the body or prolong the heart's QT interval. This increased exposure is primarily due to inhibition of Dofil's renal clearance pathway (renal cation transport system) or its metabolism via the CYP3A4 enzyme.

Contraindicated medicines and categories include:

• Renal Cation Transport Inhibitors: Cimetidine, trimethoprim (and trimethoprim/sulfamethoxazole), verapamil, dolutegravir, prochlorperazine, megestrol.
• CYP3A4 Inhibitors: Ketoconazole.
• Diuretics: Hydrochlorothiazide (alone or with triamterene) due to increased Dofil exposure and the risk of low potassium levels.

Other Pharmacodynamic Interactions

Concomitant use with other drugs that are known to prolong the QT interval is restricted, as the combined effect may further increase the risk of dangerous arrhythmias. In addition, the use of potassium-depleting diuretics is restricted because low potassium levels (hypokalemia) increase the potential for Torsade de Pointes; potassium and magnesium levels must be monitored and maintained within the normal range prior to and during treatment.

How Dofil Works: The Mechanism of Action

Dofil (Fluconazole) intervenes at a crucial stage of fungal cell development by employing a highly selective mechanism. The primary action is the specific non-competitive inhibition of the fungal enzyme Lanosterol 14alpha-demethylase (CYP51A1). This enzyme is essential for creating ergosterol, the vital structural component of the fungal cell membrane, which differs from cholesterol in human cells. This molecular engagement begins the cascade that limits the creation of this structural building block.

Blocking the CYP51A1 enzyme directly disrupts the ergosterol biosynthesis pathway, causing abnormal, toxic 14alpha-methyl sterols to accumulate inside the cell. When these faulty compounds are incorporated into the cell's outer membrane, they compromise its structural integrity and permeability. This leads to fungistatic activity—a molecular and cellular sequence that arrests the pathogen's ability to multiply and spread.

This mechanism's function is constrained by biological factors like fungal efflux pumps, which actively transport Dofil out of the cell, and the ability to overexpress or mutate the CYP51A1 enzyme. These evasion mechanisms reduce drug concentration at the target site, representing inherent limitations to the drug’s intended fungistatic activity.

How to Use Dofil

Administration of Dofil (dofetilide) follows a strictly defined protocol to ensure proper dosing and monitoring. The medicine is taken orally in capsule form, generally twice daily at approximately 12-hour intervals, and can be taken with or without food.

Official Administration Guidelines

Procedural Component	Official Requirement
Initiation Setting	The first dose and any re-initiation must occur during a minimum 3-day hospitalization with continuous ECG monitoring.
Dosing Determination	The dose is individualized based on calculated creatinine clearance (CrCl), which assesses kidney function, and the QTc interval on the ECG.
Dose Adjustment Rule	The dose must be reduced or therapy discontinued if the QTc interval exceeds specific limits defined in the prescribing information during the initial monitoring period.
Missed Dose	If a dose is missed, the next scheduled dose should be taken at the regular time. A double dose must not be taken to compensate for the missed dose.
Age Group Rule	Use in pediatric patients (under 18 years) has not been established. Dose for patients 65 years old and older is determined by renal function and QTc monitoring.

This structured approach, requiring inpatient administration for dose stabilization and continuous cardiac monitoring, ensures the medicine is used according to the precise guidelines established for this therapy.

Research Evidence / Overview of Studies for Dofil

---

Evidence for Use in Systemic and Invasive Candidiasis

Research examining Dofil for serious, deep-seated fungal infections, such as those that have entered the bloodstream (candidemia), primarily relied on short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies were used to explore outcomes related to systemic imbalance, specifically looking at how the fungal infection was cleared (microbiological outcomes) and the overall survival patterns of patients over defined time intervals. Trials were designed to evaluate Dofil against other antifungal agents. Research describes patterns related to survival rates across the groups studied.

What remains uncertain is the consistency of findings for specific groups, such as critically ill patients, where physiological strain is high. While the majority of evidence focuses on the most common fungal species, data are still emerging and limited for certain less common Candida strains.

---

Evidence for Use in Cryptococcal Meningitis

Research explored Dofil for managing fungal infections affecting the central nervous system, particularly cryptococcal meningitis. Studies monitored the rate at which the fungus was cleared from the spinal fluid and explored how symptoms evolved in the observed populations. Evidence was largely derived from studies involving immunocompromised individuals, primarily those with HIV/AIDS. For the initial management phase, studies examined whether Dofil monotherapy provided outcomes comparable to those from combination regimens, reporting that clearance rates were sometimes slower. However, for long-term suppressive treatment following the acute phase, research highlights changes measured during the study period, reporting recurrence rates observed in those trials.

Data for certain groups remain insufficient, as the evidence is heavily weighted toward the HIV/AIDS population. Research is ongoing to better understand resistance patterns that may emerge when the medicine is used for long periods.

Key Studies & References

1. Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV - WHO 2022 Update

Common questions about Dofil (FAQ)

Q: Is Dofil used for short-term or long-term treatment?

According to the official product information, Dofil is used for various fungal infections. This includes treatment for both short-term, acute problems and for certain conditions, the medicine may be used as long-term suppressive treatment.

Q: What are the signs of a serious reaction to Dofil?

Official regulatory documents describe rare but serious reactions related to the liver and skin. Signs of severe liver problems can include jaundice (yellowing of the skin), while serious skin reactions may appear as severe or extensive rashes (like Stevens-Johnson syndrome).

Q: What are the signs that Dofil is actually working?

The general purpose of Dofil is its fungistatic action, meaning it helps halt the multiplication of the fungus. Studies and official information indicate that the effectiveness of the drug is measured clinically by a reduction in the fungal load in the body and clearance of the infection.

Q: Can the effects of Dofil wear off over time?

Official documents note that some fungi can develop resistance patterns that may limit the drug's intended activity over time. This can occur due to biological factors like fungal efflux pumps, which actively transport the medicine out of the cell.

Q: Is Dofil safe for patients with a history of heart issues?

For individuals with certain heart conditions that may lead to irregular heart rhythms, caution and monitoring are officially specified during the use of Dofil. This is due to the documented risk of QTc interval prolongation, which is a specific change in the heart’s electrical activity.

Q: What official warning labels are associated with Dofil?

The official safety information highlights warnings regarding rare but serious health events. These include risks of liver injury (hepatic toxicity), severe skin reactions, and certain cardiac arrhythmias (Torsades de pointes).

Q: Why is Dofil often mentioned in discussions about drug monitoring programs?

The need for specific medical monitoring is detailed in the official administration guidelines. This monitoring includes continuous ECG measurements of the QTc interval and calculations of kidney function (creatinine clearance) to help determine the appropriate individualized use.

Q: Why is it important to check the expiration date of Dofil?

Regulatory documents specify clear shelf life and stability limits for Dofil. These limits are established to ensure the quality of the medicine, and official information indicates the product should not be used past the expiration date, or beyond the stated stability limit, such as the 14-day limit for the liquid oral suspension after it has been mixed.

Q: Does Dofil typically cause weight gain or weight loss?

According to the official product information, changes in body weight (gain or loss) are not listed among the commonly reported side effects of Dofil.

Q: Is hair loss a reported side effect of Dofil?

Studies and official information indicate that hair loss, medically known as alopecia, has been reported as an uncommon side effect of Dofil.

Q: Does Dofil affect sleep patterns?

Official regulatory documents indicate that Dofil may affect sleep patterns. The list of documented adverse reactions includes reports of both insomnia (difficulty sleeping) and somnolence (drowsiness).

Q: What common over-the-counter pain relievers interact with Dofil?

Official regulatory documents do not list specific contraindications for the concurrent use of common over-the-counter pain relievers such as ibuprofen or acetaminophen. However, other medication interactions are listed in the full product information.

Q: Does Dofil interact with herbal supplements like St. John's Wort?

While the full product information lists interactions with certain body enzymes, herbal products such as St. John's Wort are not specifically named as being either contraindicated or cautioned against in the official documents.

Q: Is it safe to consume alcohol while taking Dofil?

The official regulatory documents do not list any specific contraindication or interaction warning related to the consumption of alcohol while taking Dofil.

Q: Can Dofil be taken with vitamin supplements?

Official regulatory documents do not list any specific contraindication or interaction warning related to the use of common vitamin supplements while taking Dofil.

Q: Does Dofil affect birth control or hormone therapy?

Official drug interaction information notes that Dofil is a moderate inhibitor of a liver enzyme that processes certain substances. This action may increase the blood concentrations of estrogen and progestin, which are components of many oral contraceptives.

Q: How long does Dofil stay in the body after the last use?

The time Dofil stays in the body is characterized by its half-life, which is the time it takes for half of the drug to be eliminated. The half-life of the active ingredient in Dofil is officially described in pharmacological documents as approximately 30 hours.

Q: What research is available about Dofil's long-term safety?

Official safety data is collected and reported across studies of all durations, including prolonged use. Regulatory documents summarize observed rare and serious events, such as hepatic (liver) or cardiac (heart) toxicity, that may occur with the use of the medicine.

Q: What is the meaning of the letter code (e.g., 'IR,' 'ER') that sometimes follows the drug name Dofil?

The letter codes often describe how the medicine is released into the body. For example, the official forms of the product may use abbreviations such as IR for Immediate Release, or ER for Extended Release, which refer to different delivery mechanisms.

Q: What is a 'therapeutic window' related to Dofil?

The 'therapeutic window' refers to the range between the minimum concentration of the drug needed to produce an effect and the concentration at which toxic effects start to appear. Official prescribing information defines the concentration ranges related to effectiveness and potential toxicity for Dofil.

Q: Does Dofil have an effect on mood or anxiety?

The list of adverse reactions described in the official product information includes reports of changes in emotional state. These have included depression and anxiety.

Q: Can Dofil be used by people with kidney problems?

Official guidelines state that caution and monitoring are applied for individuals with impaired kidney function. For those with a creatinine clearance (a measure of kidney function) of leq 50 mL/min, a maintenance dose reduction is officially specified.

Q: Does age affect a person's eligibility to take Dofil?

Yes, eligibility is defined across a wide range, as Dofil is approved for use in neonates (from birth) and older adults. Dosage for older adults is typically adjusted based on their kidney function.

Q: What is the official information regarding Dofil and breastfeeding?

Official information states that the use of Dofil is generally permitted after a single, low-dose treatment. However, repeated or high-dose regimens are typically not recommended due to the potential concentration of the active ingredient in breast milk.

How to Store and Dispose of Dofil (Fluconazole)

Storage Requirement	Condition
Temperature (Tablets/Powder)	Store below 30 C (86 F) (Controlled Room Temperature).
Temperature (Liquid Forms)	Store between 5 C and 30 C; liquid forms must not be frozen.
Protection	Keep in the container it came in, ensuring it is tightly closed to protect from moisture.
Stability	Discard the reconstituted oral suspension after 14 days; do not use it past this stability limit.

Handling and Disposal

Dofil must be stored out of the sight and reach of children for safety, often requiring a locked cabinet or safety cap. Disposal of unused or expired product must be carried out according to local and national regulations for pharmaceutical waste. Do not release the product into the environment, such as by flushing it down a toilet or throwing it into general wastewater.